Study Group: Medical Device Patent Experts: Lawyers (US)
Council Members in this Study Group: 77
This study group may include professors, attorneys, former regulatory officers, and consultants knowledgeable on topics such as law and litigation issues, lobbying, policy and government, elections, antitrust, immigration, intellectual property, and legislation, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Stephen BentPartner
FOLEY & LARDNER LLP
Stephen A. Bent is Partner and former co-leader of the Life Sciences Industry Team at Foley & Lardner in Washington, DC. He is also a member of the Biotechnology & Pharmaceutical Practice Group and the Health Care and Nanotechnology Industry Teams. Mr....
Patrick Joseph IgoeLife Sciences Patent Attorney
Independent IP Litigation ConsultantPatrick Joseph Igoe is a consultant and registered patent attorney in New York. His focus is patent issues throughout Life Sciences - for example, diagnostic/therapeutic assays; medical devices/imaging technologies; Rx antibiotics, biologics, drugs, and...
Thomas SaundersOf Counsel
RISSMAN HENDRICKS & OLIVERIO, LLPThomas Saunders is an Of Counsel at Rissman Hendricks & Oliverio. He specializes in representing emerging medical technology, biotechnology/genetic engineering and pharmaceutical concerns, particularly as to patent prosecution, patent strategy, IP licensing...
Marc ScheinesonPartner & Chair, Food and Drug Practice
ALSTON & BIRD LLPMarc Scheineson is a Partner with Alston & Bird where he heads the firm's Food and Drug Law Practice. He has practiced food and drug law, health care law and administrative law for over 20 years in national law firms and at the FDA. His practice focuses...
- Joel Bock
Partner
SONNENSCHEIN, NATH & ROSENTHAL, LLP
Joel N. Bock is a Partner in the New Jersey office of Sonnenschein. Mr. Bock counsels companies regarding a wide range of intellectual property issues and structuring and negotiating transactions involving IP assets, including mergers and acquisitions,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
April 2, 2009
Teva Introduces First Generic Adderall XR® Capsules in the United States | www.tevapharm.com
(1) As stated in the 02 Apr 2009 Press Release, Teva Pharmaceutical Industries Ltd. (NasdaqGS:TEVA) has launched its generic versions corresponding to the FDA-approved Orange Book Reference Listed Drug (RLD) medical products of ADDERALL XR Capsules (mixed salts of a single-entity amphetamine product; strengths/mg: 5 10 15 20 25 30) of Shire PLC (NasdaqGS:SHPGY). This event, although unfavorable to Shire, was clearly a known possibility. Its anticipated impact will likely be a decrease in Shire's American sales of ADDERALL XR Capsules. (2) Spillover damage for American sales of VYVANSE Capsules (lisdexamfetamine dimesylate; strengths/mg: 20 30 40 50 60 70) might be possible. The nexus between ADDERALL and VYVANASE follows. VYVANASE's Active Product Ingredient (API) is lisdexamfetamine dimesylate; a prodrug of dextroamphetamine. ADDERALL's APIs are a mixture of 4 related amphetamines. Thus, ADDERAL and VYVANASE are related medical products.
-
OXYCONTIN Update: Ratiopharm And Sandoz Infringe 2 European Patents Controlled By Napp And Purdue
April 2, 2009
OXYCONTIN Update: England Patent Infringement Victory {Napp Pharmaceutical Holdings Ltd v Ratiopharm GmbH [2009] EWCA Civ 252 (01 April 2009)} | www.bailii.org
(1) In this article, the London 01 Apr 2009 html version of judgment of the England and Wales Court of Appeal (Civil Division), a recent appellate court decision provides Napp and Purdue, in protecting OXYCONTIN, with a definitive patent infringement victory over both Ratiopharm GmbH and Sandoz Ltd (winners at the prior lower court). (2) Its conclusion at Paragraph No. 117 is clear and unambiguous. "The patents are valid and infringed." (3) This important decision reverses a prior 16 Dec 2008 decision. From a financial point of view OXYCONTIN is vital - "Its importance is shown by its sales figures - of the order of £32 million per annum in the UK alone." (Paragraph No. 4)
-
March 30, 2009
Teva (NasdaqGS:TEVA) Announces FDA Response to Citizen Petition (Re COPAXONE ANDA) | www.tevapharm.com
As stated in the 25 Mar 2009 press release by Teva (NasdaqGS:TEVA), the FDA recently denied Teva's Citizen Petition (CP) which was previously filed 26 Sep 2008. Teva is now fully-engaged in its dual efforts to protect its American COPAXONE sales. These dual efforts are (1) at the FDA: through petition practice, Teva seeks to have the FDA undertake specific action which in effect would either delay or prevent FDA review or approval of the now pending Novartis-Momenta Abbreviated New Drug Application No. 90-128 for generic COPAXONE; and (2) at the United States District Court for the Southern District of New York (USDC/SDNY): in Case No. 1:08-cv-07611-BSJ-JCF, Teva as Plaintiff has sued Novartis (NYSE:NVS) and Momenta (NasdaqGM:MNTA) for patent infringement of multiple FDA Orange Book patents [7 patents are listed in the FDA Orange Book 5981589 6054430 6342476 6362161 6620847 6939539 7199098].
-
March 25, 2009
Cubist Pharmaceuticals Files Patent Infringement Lawsuit Against Teva Parenteral Medicines, Inc. | www.cubist.com
As noted in the Mon 23 Mar 2009 press release, Cubist has sued Teva in response to Teva's Abbreviated New Drug Application (ANDA) seeking FDA approval of a generic version of CUBICIN. This patent dispute is critical because, as noted in recent SEC filings, CUBICIN sales account for substantially all of Cubist's revenues. Within the 3 patents-in-suit, 2 patents (US Patent Nos. 6468967 6852689) contain only method claims while the remaining 1 patent (US Reissue Pat. No. 39071) contains compound, composition, formulation, and method claims.
-
MULTAQ (dronderone hydrochloride) NDA - Sanofi-Aventis Awaits FDA Final Decision
March 23, 2009
Heart-Drug Review Gives Sanofi Shot at $1.9 Billion (Update2) | www.bloomberg.com
As indicated in the Tue 17 Mar 2009 Bloomberg article, the FDA has provided Sanofi-Aventis SA (NYSE:SNY) with a positive viewpoint for current NDA No. 22-425 [submission date: 31 Jul 2008], the New Drug Application for MULTAQ (dronderone hydrochloride). However, this positive viewpoint is not the same as FDA final approval for MULTAQ; rather, it is a nonbinding and nonfinal recommendation of a committee. Analysis of the public FDA documents on this matter indicate that the positive recommendation is both complicated and nuanced.
Members in this Study Group include these company types:
- Law Firm (general practice/large)
- Law Firm (Boutique / Specialized)
Members in this Study Group often have these job titles:
- Partner
- Attorney
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
November 1, 2007 | New York
GLGi: Big Pharma v. Generics - Science Patent BattlesGLG Webcasts & Teleconferences
Leading Experts in Medical Device Patent Experts: Lawyers (US) have not participated in any GLG webcasts.
View All GLG Webcasts & Teleconferences in Legal, Economic & Regulatory Affairs